Articles On Pharmaust (ASX:PAA)

Title Source Codes Date
Market Close: ASX drives uphill on continued recovery

The ASX200 closed .4 of a per cent up with IT and Health Care the locomotives of a sluggish steam energy labouring under the weight of Energy and Industrials. IT and Health Care were up 1.73 and 1.22 per cent respectively whilst Energy a... PAA 23 hours ago
Closing Bell: Tech stocks in demand ahead of Tesla results; Osteopore up 130pc on clinical trial news

The ASX extends its gains on Tuesday Tech stocks rallied ahead of US megacap earnings, while goldies struggled Tesla, along with Alphabet and Spotify, will release results tonight   The ASX200 lifted on Tuesday, up by +0.45% after trackin...

Stockhead PAA 23 hours ago
Market Update: ASX edges up with a healthier disposition

The ASX200 is trading up around half a per cent with Health Care and Real Estate leading the gains, up around 1.1 per cent. Industrials, on the other end of the scale, has fallen the heaviest, down just over half a per cent. Company... PAA 1 day ago
Market Update: ASX edges up with a healthier disposition

The ASX200 is trading up around half a per cent with Health Care and Real Estate leading the gains, up around 1.1 per cent. Industrials, on the other end of the scale, has fallen the heaviest, down just over half a per cent. Company... PAA 1 day ago
PharmAust appoints interim CEO as company plans for pivotal Phase 2/3 study

Clinical-stage biotechnology company PharmAust (ASX: PAA) has announced that chief executive officer Dr Michael Thurn has resigned from the role and will leave the company in four months. Chief operating officer John Clark has been appointe... PAA 1 day ago
PharmAust CEO sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust (ASX:PAA), shares have fallen as much as 24 per cent so far this morning, following the resignation of its CEO, Dr. Michael Thurn, citing personal reasons. PharmAust’s Chief Operating Offic... PAA 1 day ago
Closing Bell: ASX up as unemployment rate ticks higher; BHP, Nimy Resources gain

  The ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as the giant released its Q3 report Nimy Resources up 50pc after reporting promising intercepts   The ASX added 0.5% on Thursday as the unemp...

Stockhead PAA 5 days ago
PharmAust bolsters manufacturing leadership to expand path to commercialisation

Dr Herbert Brinkman joins PharmAust as head of manufacturing, bringing over 30 years of pharmaceutical product development experience Manufacturing process development agreements signed with Syngene International and Catalent Pharma Soluti...

Stockhead PAA 6 days ago
PharmAust appoints industry veteran to spearhead manufacturing ahead of critical MPL trial

Clinical-stage biotechnology company PharmAust (ASX: PAA) has strengthened its management team with the appointment of Dr Herbert Brinkman as head of manufacturing. Dr Brinkman has more than 30 years of product development and manufacturing... PAA 6 days ago
PharmAust’s pioneering monepantel MND study receives HREC green light for final phase

Clinical-stage biotechnology company PharmAust (ASX: PAA) has received approval from the human research ethics committee (HREC) at Sydney’s Macquarie University to start an open-label extension study of lead drug monepantel (MPL) on patient... PAA 2 weeks ago
Closing Bell: ASX too timid on Tuesday. Although Dart Mining has a decent Mesoblast

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Stockhead PAA 3 weeks ago
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 3

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Stockhead PAA 1 month ago
Closing Bell: ASX a little lower after hosting a Big 4 bank midweek spank

Local markets end lower on big bank sell-off Material gains offset by Telco’s and Financials  Small Caps led by rare earths developer Arafura   Local markets have not showered anyone in glory, profit or confidence on Thursday. At 4pm on T...

Stockhead PAA 1 month ago
PharmAust files groundbreaking MND/ALS clinical data with the FDA

Phase 1 MEND study outcomes for MND/ALS treatment now with FDA for review in support of PharmAust’s Orphan Drug Designation request Clinical data shows monepantel (MPL) has the potential to delay the progression of MND/ALS by ~58% PAA on t...

Stockhead PAA 1 month ago
PharmAust eyes FDA orphan drug designation for monepantel after positive MND/ALS trial results

Biotechnology company PharmAust (ASX: PAA) has filed supplementary positive data from a Phase 1 MEND trial of lead drug monepantel with the US Food and Drug Administration’s (FDA) Office of Orphan Products Development. The data was packaged... PAA 1 month ago
ASX Today: Stocks to watch on Thursday

The ASX is set to rise again today with futures up 0.28% near 8.30am AEDT. US markets had another subdued night overnight – is the YTD rally losing steam for good, or is this but a temporary lull as traders digest recent CPI? The Dow... PAA 1 month ago
Closing Bell: ASX ends higher but iron’s ordinary problem isn’t going away

  Local markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary stocks offset losses in materials and Energy  Small Caps led by LBT Innovations   It’s hard to stay afloat when BHP sinks to a near nine-m...

Stockhead PAA 1 month ago
If you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 now

Is it fanciful imagining how rich one could be if only they had invested in a particular ASX stock? I say no, because it keeps you motivated to keep researching and investing. It also reminds you that diversification can not only reduce ri...

Motley Fool PAA 1 month ago
ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results

ASX health sector rises in line with broader markets in the past five days  AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h...

Stockhead PAA 1 month ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead PAA 1 month ago
ASX February winners: The best 50 stocks as a ‘super-heroic small cap’ soars 322%

S&P/ASX 200 rose 0.8% in February with Large Cap S&P/ASX 50 underperforming Midcap and Small Ordinaries Tech sector was the big winner up 19% in February as energy and materials sector slumped  Nyrada soars after preclinical study...

Stockhead PAA 1 month ago
PharmAust reports positive top-line results from Phase 1 MEND study

PharmAust (ASX:PAA) has announced that it has met its primary safety and tolerability endpoints with monepantel in the Phase 1 MEND study.

BiotechDispatch PAA 1 month ago
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary ef...

FNArena PAA 1 month ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead PAA 1 month ago
PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy

MPL found to be safe and well tolerated by MND/ALS patients treated under PAA’s Phase 1 trial Drug also found to have reduced disease progression by about 58% This could translate to significant improvements in life expectancy for MND/ALS...

Stockhead PAA 1 month ago
This small-cap ASX stock just rocketed 39%. What's doing?

A little-known small-cap stock has rocketed on Wednesday morning after coming out of a two-day trading halt. PharmAust Limited (ASX: PAA) had requested a halt to trading of its shares before the market opened on Monday. On Tuesday evening...

Motley Fool PAA 1 month ago
PharmAust’s monepantel study shows 58% slowdown in MND progression

A Phase 1 trial into the effects of lead candidate monepantel (MPL) on patients with motor neurone disease MND / amyotrophic lateral sclerosis (ALS) has delivered top-line results for clinical-stage biotech PharmAust (ASX: PAA). The multi-c... PAA 1 month ago
Closing Bell: The ASX has come a long way and gone nowhere on Monday

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

Stockhead PAA 1 month ago
Hot Money Monday: This is what the Father of Momentum Investing thought about ‘undervalued’ stocks

Momentum investing has been shown to be a successful strategy over the long term. The strategy essentially involves “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”....

Stockhead PAA 1 month ago
Closing Bell: Thursday and the ASX200 is flat and porous. I am unhappy… But at least Bega made a lot of cheese

  Local markets end flat like an old can of coke on the coffee table Sectors are mixed up. I’m mixed up after all that Small Caps led by Way2VAT again, as well as some cracking local medtechs   It is 4pm on Thursday February 22, and the S...

Stockhead PAA 2 months ago
PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS

PharmAust engages globally renowned experts in MND/ALS to form a scientific advisory board (SAB) The SAB will provide expert advice for the development of monepantel to treat MND/ALS The SAB will also support the planning stages for Pharm...

Stockhead PAA 2 months ago
PharmAust assembles world-class scientific advisory board to propel fight against neurodegenerative diseases

Perth-based clinical-stage biotechnology company PharmAust (ASX: PAA) has pulled together a team of leading scientists to support the investigation of its lead treatment candidate monepantel (MPL). PharmAust is focused on repurposing MPL fo... PAA 2 months ago
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

Stockhead PAA 2 months ago
Market Close: Materials lead charge as market gains 0.7pc

The ASX200 closed the day up about .7 of a per cent. Most sectors finished in the green, led by materials, up 1.5 per cent. BHP Group is considering putting on hold its WA Nickel operations – due to a major drop in nickel prices. In r... PAA 2 months ago
Closing Bell: Material gains for the ASX on Friday while a good week at work sees Tech Sector gain 7.5pc

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

Stockhead PAA 2 months ago
PharmAust’s monepantel study for MND treatment on fast track after FDA meeting

PharmAust (ASX: PAA) has achieved another significant milestone along the path to gaining approval for the use of monepantel (MPL) in the treatment of motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). The company has received p... PAA 2 months ago
Closing Bell: Local markets in a sulk for the cut that won’t come

ASX200 ends 0.75pc lower after a long slog back from -1.5pc this morning. Industrial Sector only gainer, thanks to a banger from Downer Edi Small caps led by Blue Star Helium, Rox Resources.   Local share markets trimmed early losses b...

Stockhead PAA 2 months ago
PharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’

PharmAust announces first patient dosed in 12-month OLE study for patients with MND/ALS All 12 patients from Phase 1 MEND study expected to be enrolled after meeting minimum requirement Analysis shows a 100% survival rate among the 12 Phas...

Stockhead PAA 2 months ago
PharmAust begins extended study on promising MND treatment following successful trial

Biotechnology company PharmAust (ASX: PAA) has dosed the first patient in an open-label extension (OLE) study follow-up to a program which has obtained promising initial results. The OLE study will investigate the long-term safety, tolerabi... PAA 2 months ago
PharmAust trial heralds new era of hope for motor neurone disease patients

Perth-headquartered clinical-stage biotechnology company, PharmAust (ASX: PAA), has hit another milestone in the assessment of its potential motor neurone disease (MND) treatment monepantel (MPL). The company reports that all patients have... PAA 4 months ago
Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Drug developer, Pharmaust (ASX:PAA) announces all 12 patients are finished with its phase one MEND study using monepantel (MPL)for Motor Neuron Disease (MND) Each patient received increasing dosages in a staggered approach with the highe... PAA 4 months ago
Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market

PharmAust says progression of its programs show it is a strong contender to compete in rare diseases market Deals done in rare disease market increasing as big pharma realises potential of an orphan drug designation PharmAust progressing s...

Stockhead PAA 5 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead PAA 5 months ago
PharmAust progresses MPL programs for treatment of motor neurone disease and canine oncology

Biotechnology company PharmAust (ASX: PAA) has progressed its monepantel (MPL) clinical programs for motor neurone disease and canine oncology during the period to end September. The company’s Phase 1 MEND motor neurone disease study was co... PAA 5 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead PAA 6 months ago
PharmAust says final MND patient in cohort 4 successfully completes dosing

PharmAust (ASX:PAA) has announced that all patients in Cohort 4 have completed dosing in its Phase 1 MEND study of monepantel (MPL) in patients with motor neurone disease (MND/ALS). The company...

BiotechDispatch PAA 6 months ago
TMH Market Update: Newmont’s mega-deal to acquire Newcrest nears closure

The ASX200 has slipped more than .3 of a per cent in early trade. And that’s a performance that’s slightly better than futures had suggested. Inflation data in this morning shows China’s economy remained stagnant in September with no cha... PAA 6 months ago
PharmAust completes dosing in phase one MND trial

PharmAust (ASX:PAA) wraps up cohort four of its phase one MEND study using MPL at 10 mg/kg to treat MND The study is supported by Australia’s largest independent not-for-profit organisation for MND research, FightMND PAA is using the... PAA 6 months ago
PharmAust hits major milestone in motor neurone disease treatment study

Perth-headquartered clinical-stage biotechnology company PharmAust (ASX: PAA) has achieved a significant milestone with the final dosing of patients participating in the assessment of a treatment for the fatal motor neurone disease (MND/ALS... PAA 6 months ago
PharmAust eyes US orphan drug designation after successful phase 1 motor neurone disease trial

PAA has finished does all patients in cohort 4 of its phase 1 study in MND/ALS Data from phase 1 expected in Q1 CY24 before a phase 2 trial commences Phase 1 data will support US orphan drug designation application MND/ALS addressable mark...

Stockhead PAA 6 months ago